Black­stone re­con­sid­ers fu­ture of Japan­ese phar­ma — re­port

Black­stone is re­port­ed­ly pon­der­ing the fu­ture of Ayu­mi Phar­ma­ceu­ti­cal, the Japan­ese phar­ma com­pa­ny it struck a deal to ac­quire three years ago.

Un­named sources told Bloomberg that the in­vest­ment firm is con­sid­er­ing mul­ti­ple pos­si­bil­i­ties, in­clud­ing an IPO and a sale that could val­ue Ayu­mi at $1 bil­lion-plus. It may al­so keep the busi­ness.

Ayu­mi was formed back in 2015, when San­ten Phar­ma­ceu­ti­cal’s rheuma­tism busi­ness linked up with Showa Yakuhin Kako’s med­ical busi­ness. It’s known for the ac­eta­minophen painkiller Calon­al, which was Showa Yakuhin Kako’s lead prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER